Tom H. Greene

Tom H. Greene, PhD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine , Adjunct - Family & Preventive Medicine , Primary - Population Health Sciences

Divisions: Public Health , Epidemiology

Dr. Tom Greene is a Professor of the Division of Biostatistics in the Department of Population Health Sciences, and a Professor in the Division of Epidemiology of the Department of Internal Medicine. He is also Director of the Population Health Research Foundation in the Utah Center for Clinical and Translational Science, and currently holds an H.A. and Edna Benning Endowed Chair. Dr. Greene received his PhD in Statistics from Cornell University in 1985, and worked as an Assistant Professor in the Department of Statistics at the University of Kentucky from 1985 to 1989. He then served as a statistician at Case Western University and the Cleveland Clinic Foundation from 1989 through 2006, where he was the lead statistician on a substantial number of multi-center clinical trials, primarily in the field of Nephrology. Dr. Greene was the acting head of the Cleveland Clinic’s Cancer Biostatistics Core for 2 years from 1991-1993. Dr. Greene moved to the University of Utah in 2006, where he founded the Study Design and Biostatistics Center and subsequently the Population Health Research Foundation.

Dr. Greene serves as the lead statistician on many research projects in collaboration with clinical and translational investigators across the University of Utah and elsewhere, and carries out methodological research in the areas of clinical trial design, causal inference, and validation of surrogate endpoints. Dr. Greene is also a member of the Cancer Biostatistics Resource, and is involved in the design and analysis of a sequential, multiple assignment, randomized trial to promote smoking cessation. He is particularly interested in the problem of integrating information from multiple surrogate and clinical endpoints to evaluate treatment efficacy in randomized clinical trials.

Education History

Undergraduate University of Kentucky
 BS
Graduate Training Cornell University
 MS
Doctoral Training Cornell University
 PhD

Selected Publications

Journal Article

  1. Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M, African American Study of Kidney Disease and Hypertension Trial Study Group (2006). Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. American journal of kidney diseases, 47(6), 956-64. (Read full article)
  2. Greene T, Daugirdas JT, Depner TA, Gotch F, Kuhlman M, Frequent Hemodialysis Network Study Group., National Institute of Diabetes and Digestive and Kidney Diseases., National Institutes of Health (2009). Solute clearances and fluid removal in the frequent hemodialysis network trials. American journal of kidney diseases, 53(5), 835-44. (Read full article)
  3. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group (2006). Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American journal of kidney diseases, 48(5), 739-51. (Read full article)
  4. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. American journal of kidney diseases, 58(5), 729-36. (Read full article)
  5. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis (2020). Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American journal of kidney diseases, 75(1), 84-104. (Read full article)
  6. Edmonston DL, Roe MT, Block G, Conway PT, Dember LM, DiBattiste PM, Greene T, Hariri A, Inker LA, Isakova T, Montez-Rath ME, Nkulikiyinka R, Polidori D, Roessig L, Tangri N, Wyatt C, Chertow GM, Wolf (2020). Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. American journal of kidney diseases, 76(6), 842-850. (Read full article)
  7. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration (2006). Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of internal medicine, 145(4), 247-54. (Read full article)
  8. Fritz JM, Lane E, McFadden M, Brennan G, Magel JS, Thackeray A, Minick K, Meier W, Greene (2021). Physical Therapy Referral From Primary Care for Acute Back Pain With Sciatica : A Randomized Controlled Trial. Annals of internal medicine, 174(1), 8-17. (Read full article)
  9. Ernhart CB, Greene (1990). Low-level lead exposure in the prenatal and early preschool periods: language development. Archives of environmental health, 45(6), 342-54. (Read full article)
  10. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA, African American Study of Hypertension and Kidney Disease Collaborative Research Group (2009). Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Archives of internal medicine, 169(17), 1587-94. (Read full article)
  11. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY, African American Study of Kidney Disease and Hypertension Collaborative Research Group (2008). Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Archives of internal medicine, 168(8), 832-9. (Read full article)
  12. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris G (2005). The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Archives of internal medicine, 165(8), 947-53. (Read full article)
  13. Mayer J, Greene T, Howell J, Ying J, Rubin MA, Trick WE, Samore MH, CDC Prevention Epicenters Program (2012). Agreement in classifying bloodstream infections among multiple reviewers conducting surveillance. Clinical infectious diseases, 55(3), 364-70. (Read full article)
  14. Jones M, Ying J, Huttner B, Evans M, Maw M, Nielson C, Rubin MA, Greene T, Samore M (2014). Relationships between the importation, transmission, and nosocomial infections of methicillin-resistant Staphylococcus aureus: an observational study of 112 Veterans Affairs Medical Centers. Clinical infectious diseases, 58(1), 32-9. (Read full article)
  15. Greene (2001). A model for a proportional treatment effect on disease progression. Biometrics, 57(2), 354-60. (Read full article)
  16. Joffe MM, Greene (2009). Related causal frameworks for surrogate outcomes. Biometrics, 65(2), 530-8. (Read full article)
  17. Xu Y, Greene TH, Bress AP, Sauer BC, Bellows BK, Zhang Y, Weintraub WS, Moran AE, Shen (2020). Estimating the optimal individualized treatment rule from a cost-effectiveness perspective. Biometrics, 78(1), 337-351. (Read full article)
  18. Poggio ED, Wang X, Greene T, Van Lente F, Hall P (2005). Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. Journal of the American Society of Nephrology, 16(2), 459-66. (Read full article)
  19. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall P (1993). Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology, 4(5), 1159-71. (Read full article)
  20. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators (2011). FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. Journal of the American Society of Nephrology, 22(10), 1913-22. (Read full article)
  21. Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker L (2019). Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology, 30(9), 1756-1769. (Read full article)
  22. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. Journal of the American Society of Nephrology, 30(8), 1523-1533. (Read full article)
  23. Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene (2019). GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology, 30(9), 1735-1745. (Read full article)
  24. Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V, CREDENCE Study Investigators (2020). Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology, 31(5), 1128-1139. (Read full article)
  25. Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Mahaffey KW, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Jardine MJ, Heerspink HJ (2020). Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology, 31(12), 2925-2936. (Read full article)
  26. Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress AP, Kramer HJ, Al-Marji C, Greene T, Beddhu (2019). Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. American journal of hypertension, 32(12), 1170-1177. (Read full article)
  27. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, Navaravong L, Piccini JP, Ranjan R, Spertus JA, Stehlik J, Turner JL, Greene T, Hess R, Steinberg B (2020). Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. Journal of cardiovascular electrophysiology, 31(12), 3187-3195. (Read full article)
  28. Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Kusek JW, Selhub J, Collins AJ, Levey AS, Shlipak M (2006). Relationship between homocysteine and mortality in chronic kidney disease. Circulation, 113(12), 1572-7. (Read full article)
  29. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 140(9), 739-750. (Read full article)
  30. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration (2007). Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clinical chemistry, 53(4), 766-72. (Read full article)
  31. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, Beddhu (2020). The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Diabetes care, 43(8), 1878-1884. (Read full article)
  32. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, Canfield RL, Dietrich KN, Bornschein R, Greene T, Rothenberg SJ, Needleman HL, Schnaas L, Wasserman G, Graziano J, Roberts (2019). Erratum: "Low-Level Environmental Lead Exposure and Children's Intellectual Function: An International Pooled Analysis". Environmental health perspectives, 127(9), 99001. (Read full article)
  33. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA, Wang S (1997). Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension (Dallas, Tex., 30(3 Pt 1), 428-35. (Read full article)
  34. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension (Dallas, Tex., HYPERTENSIONAHA11912907. (Read full article)
  35. Iglesias AA, Barry GF, Meyer C, Bloksberg L, Nakata PA, Greene T, Laughlin MJ, Okita TW, Kishore GM, Preiss (1993). Expression of the potato tuber ADP-glucose pyrophosphorylase in Escherichia coli. The Journal of biological chemistry, 268(2), 1081-6. (Read full article)
  36. Beckmann JT, Wylie JD, Potter MQ, Maak TG, Greene TH, Aoki S (2015). Effect of Naproxen Prophylaxis on Heterotopic Ossification Following Hip Arthroscopy: A Double-Blind Randomized Placebo-Controlled Trial. The Journal of bone and joint surgery. American volume, 97(24), 2032-7. (Read full article)
  37. Greene T, Ernhart C (1991). Adjustment for cofactors in pediatric research. Journal of developmental and behavioral pediatrics, 12(6), 378-85. (Read full article)
  38. Ogiste JS, Nejat RJ, Rashid HH, Greene T, Gupta (2003). The role of mannitol in alleviating renal injury during extracorporeal shock wave lithotripsy. The Journal of urology, 169(3), 875-7. (Read full article)
  39. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS, Frequent Hemodialysis Network Trial Group (2007). Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney international, 71(4), 349-59. (Read full article)
  40. Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer B (2019). An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney international, 96(3), 750-760. (Read full article)
  41. Heerspink HJ, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC, DAPA-CKD trial committees and investigators (2021). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney international, 101(1), 174-184. (Read full article)
  42. Samore MH, Shen S, Greene T, Stoddard G, Sauer B, Shinogle J, Nebeker J, Harbarth (2007). A simulation-based evaluation of methods to estimate the impact of an adverse event on hospital length of stay. Medical care, 45(10 Supl 2), S108-15. (Read full article)
  43. Garg AX, Greene T, Levin N (2008). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrology, dialysis, transplantation, 23(1), 52-5. (Read full article)
  44. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators (2020). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology, dialysis, transplantation, 35(2), 274-282. (Read full article)
  45. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJ (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology, dialysis, transplantation, 35(10), 1700-1711. (Read full article)
  46. Heerspink HJL, Stack AG, Terkeltaub R, Greene TA, Inker LA, Bjursell M, Perl S, Rikte T, Erlandsson F, Perkovic V, SAPPHIRE investigators (2021). Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrology, dialysis, transplantation, (Read full article)
  47. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of medicine, 380(24), 2295-2306. (Read full article)
  48. Stevens LA, Coresh J, Greene T, Levey A (2006). Assessing kidney function--measured and estimated glomerular filtration rate. The New England journal of medicine, 354(23), 2473-83. (Read full article)
  49. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study Group (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. The New England journal of medicine, 347(25), 2010-9. (Read full article)
  50. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020). Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine, 383(15), 1436-1446. (Read full article)
  51. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS, Chronic Kidney Disease Epidemiology Collaboration (2021). New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. The New England journal of medicine, (Read full article)
  52. Torrecillas V, Allen CM, Greene T, Park A, Chung W, Lanzieri TM, Demmler-Harrison (2020). Should You Follow the Better-Hearing Ear for Congenital Cytomegalovirus Infection and Isolated Sensorineural Hearing Loss?. Otolaryngology--head and neck surgery, 162(1), 114-120. (Read full article)
  53. Lane E, Magel JS, Thackeray A, Greene T, Fino NF, Puentedura EJ, Louw A, Maddox D, Fritz J (2021). Effectiveness of training physical therapists in pain neuroscience education for patients with chronic spine pain: cluster-randomized trial. Pain, 163(5), 852-860. (Read full article)
  54. Nkoy FL, Fassl BA, Wilkins VL, Johnson J, Unsicker EH, Koopmeiners KJ, Jensen A, Frazier M, Gaddis J, Malmgren L, Williams S, Oldroyd H, Greene T, Sheng X, Uchida DA, Maloney CG, Stone B (2019). Ambulatory Management of Childhood Asthma Using a Novel Self-management Application. Pediatrics, 143(6), (Read full article)
  55. Hu B, Li L, Wang X, Greene (2012). Nonparametric multistate representations of survival and longitudinal data with measurement error. Statistics in medicine, 31(21), 2303-17. (Read full article)
  56. Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, Inker L, Greene (2019). Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Statistics in medicine, 38(22), 4218-4239. (Read full article)
  57. Steinberg BA, Zhang M, Bensch J, Lyons A, Bunch TJ, Piccini JP, Siu A, Spertus JA, Stehlik J, Wohlfahrt P, Greene T, Hess R, Fang J (2021). Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. Journal of cardiac failure, 28, 13-20. (Read full article)
  58. Kevin Rogers R, Stehlik J, Stoddard GJ, Greene T, Collins SP, Peacock WF, Maisel AD, Clopton P, Michaels A (2009). Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. European journal of heart failure, 11(11), 1043-9. (Read full article)
  59. Leecaster M, Gesteland P, Greene T, Walton N, Gundlapalli A, Rolfs R, Byington C, Samore (2011). Modeling the variations in pediatric respiratory syncytial virus seasonal epidemics. BMC infectious diseases, 11, 105. (Read full article)
  60. Skolasky RL, Wegener ST, Aaron RV, Ephraim P, Brennan G, Greene T, Lane E, Minick K, Hanley AW, Garland EL, Fritz J (2020). The OPTIMIZE study: protocol of a pragmatic sequential multiple assessment randomized trial of nonpharmacologic treatment for chronic, nonspecific low back pain. BMC musculoskeletal disorders, 21(1), 293. (Read full article)
  61. Gallicchio L, Miller SR, Kiefer J, Greene T, Zacur HA, Flaws J (2016). The Associations Between Body Mass Index, Smoking, and Alcohol Intake with Ovarian Volume in Midlife Women. Journal of women's health (2002), 25(4), 409-15. (Read full article)
  62. Fritz JM, Rhon DI, Teyhen DS, Kean J, Vanneman ME, Garland EL, Lee IE, Thorp RE, Greene T (2020). A Sequential Multiple-Assignment Randomized Trial (SMART) for Stepped Care Management of Low Back Pain in the Military Health System: A Trial Protocol. Pain medicine (Malden, Mass.), 21(Suppl 2), S73-S82. (Read full article)
  63. Johnson JT, Sullivan KL, Nelson RE, Sheng X, Greene TH, Bailly DK, Eckhauser AW, Marino BS, Minich LL, Pinto N (2020). Factors That Contribute to Cost Differences Based on ICU of Admission in Neonates Undergoing Congenital Heart Surgery: A Novel Decomposition Analysis. Pediatric critical care medicine, 21(9), e842-e847. (Read full article)
  64. Khader K, Leecaster M, Greene T, Samore M, Thomas (2014). Improved hidden Markov model for nosocomial infections. Mathematical medicine and biology, 31(4), 338-52. (Read full article)
  65. Thomas A, Redd A, Khader K, Leecaster M, Greene T, Samore (2015). Efficient parameter estimation for models of healthcare-associated pathogen transmission in discrete and continuous time. Mathematical medicine and biology, 32(1), 79-98. (Read full article)
  66. Rubin MA, Mayer J, Greene T, Sauer BC, Hota B, Trick W, Jernigan JA, Samore M (2008). An agent-based model for evaluating surveillance methods for catheter-related bloodstream infection. AMIA ... Annual Symposium proceedings. AMIA Symposium, 631-5. (Read full article)
  67. Yan G, Greene (2011). Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trials. Clinical trials (London, England), 8(5), 571-80. (Read full article)
  68. Fernandez ME, Schlechter CR, Del Fiol G, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Greene T, Nahum-Shani I, Schulthies S, Nelson M, Bohner C, Kramer H, Borbolla D, Austin S, Weir C, Walker TW, Lam CY, Wetter D (2020). QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implementation science, 15(1), 9. (Read full article)
  69. Stevens LA, Greene T, Levey A (2006). Surrogate end points for clinical trials of kidney disease progression. Clinical journal of the American Society of Nephrology, 1(4), 874-84. (Read full article)
  70. Zuk A, Palevsky PM, Fried L, Harrell FE Jr, Khan S, McKay DB, Devey L, Chawla L, de Caestecker M, Kaufman JS, Thompson BT, Agarwal A, Greene T, Okusa MD, Bonventre JV, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star R (2018). Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Clinical journal of the American Society of Nephrology, 13(7), 1113-1123. (Read full article)
  71. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, Beddhu (2020). Sodium Bicarbonate Supplementation and Urinary TGF-ß1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. Clinical journal of the American Society of Nephrology, 15(2), 200-208. (Read full article)
  72. Brintz BJ, Howard JI, Haaland B, Platts-Mills JA, Greene T, Levine AC, Nelson EJ, Pavia AT, Kotloff KL, Leung D (2020). Clinical predictors for etiology of acute diarrhea in children in resource-limited settings. PLoS neglected tropical diseases, 14(10), e0008677. (Read full article)
  73. Greene T, Joffe M, Hu B, Li L, Boucher (2013). The balanced survivor average causal effect. The international journal of biostatistics, 9(2), 291-306. (Read full article)
  74. Levey AS, Coresh J, Tighiouart H, Greene T, Inker L (2020). Measured and estimated glomerular filtration rate: current status and future directions. Nature reviews. Nephrology, 16(1), 51-64. (Read full article)
  75. Li L, Luo S, Hu B, Greene (2017). Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease. Statistics in biosciences, 9(2), 357-378. (Read full article)
  76. Akhlaghi N, Needham DM, Bose S, Banner-Goodspeed VM, Beesley SJ, Dinglas VD, Groat D, Greene T, Hopkins RO, Jackson J, Mir-Kasimov M, Sevin CM, Wilson E, Brown S (2020). Evaluating the association between unmet healthcare needs and subsequent clinical outcomes: protocol for the Addressing Post-Intensive Care Syndrome-01 (APICS-01) multicentre cohort study. BMJ open, 10(10), e040830. (Read full article)
  77. Nkoy FL, Wilkins VL, Fassl BA, Johnson JM, Uchida DA, Poll JB, Greene TH, Koopmeiners KJ, Reynolds CC, Valentine KJ, Savitz LA, Maloney CG, Stone B (2019). Contextual Factors Influencing Implementation of Evidence-Based Care for Children Hospitalized With Asthma. Hospital pediatrics, 9(12), 949-957. (Read full article)
  78. Jones BE, Ying J, Stevens V, Haroldsen C, He T, Nevers M, Christensen MA, Nelson RE, Stoddard GJ, Sauer BC, Yarbrough PM, Jones MM, Goetz MB, Greene T, Samore M (2020). Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA internal medicine, 180(4), 552-560. (Read full article)
  79. Coon ER, Destino LA, Greene TH, Vukin E, Stoddard G, Schroeder A (2020). Comparison of As-Needed and Scheduled Posthospitalization Follow-up for Children Hospitalized for Bronchiolitis: The Bronchiolitis Follow-up Intervention Trial (BeneFIT) Randomized Clinical Trial. JAMA pediatrics, 174(9), e201937. (Read full article)
  80. Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, Buckel WR, Srivastava R, Harris ES, Leither LM, Johnson SA, Paine R 3rd, Greene (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Annals of the American Thoracic Society, 17(8), 1008-1015. (Read full article)
  81. Brown SM, Peltan I, Kumar N, Leither L, Webb BJ, Starr N, Grissom CK, Buckel WR, Srivastava R, Butler AM, Groat D, Haaland B, Ying J, Harris E, Johnson S, Paine R 3rd, Greene (2020). Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. Annals of the American Thoracic Society, (Read full article)
  82. Jones BE, Ying J, Nevers M, Alba PR, He T, Patterson OV, Jones MM, Stevens V, Shen J, Humpherys J, Peterson KS, Rutter ED, Gundlapalli AV, Weir CR, Dean NC, Fine MJ, Samore MC, Greene T (2021). Computerized Mortality Prediction for Community-acquired Pneumonia at 117 Veterans Affairs Medical Centers. Annals of the American Thoracic Society, 18(7), 1175-1184. (Read full article)
  83. Staub J, Siddiqui A, Murphy M, Lam R, Parikh M, Pleskow D, Papachristou G, Sharaiha R, Iqbal U, Loren D, Kowalski T, Noor A, Mumtaz T, Yasuda I, Thomas S, Hsaeeb A, Herrick J, Greene T, Adler D (2020). Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study. Annals of gastroenterology, 33(2), 202-209. (Read full article)
  84. Hammers DB, Foster NL, Hoffman JM, Greene TH, Duff (2019). Neuropsychological, Psychiatric, and Functional Correlates of Clinical Trial Enrollment. The journal of prevention of Alzheimer's disease, 6(4), 242-247. (Read full article)
  85. Wohlfahrt P, Nativi-Nicolau J, Zhang M, Selzman CH, Greene T, Conte J, Biber JE, Hess R, Mondesir FL, Wever-Pinzon O, Drakos SG, Gilbert EM, Kemeyou L, LaSalle B, Steinberg BA, Shah RU, Fang JC, Spertus JA, Stehlik (2021). Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction. JAMA cardiology, 6(8), 957-962. (Read full article)
  86. Delaney RK, Pinto NM, Ozanne EM, Stark LA, Pershing ML, Thorpe A, Witteman HO, Thokala P, Lambert LM, Hansen LM, Greene TH, Fagerlin (2021). Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. BMJ open, 11(12), e055455. (Read full article)
  87. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress A (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open, 5(1), e2143001. (Read full article)
  88. Brown SM,Dinglas VD,Akhlaghi N,Bose S,Banner-Goodspeed V,Beesley S,Groat D,Greene T,Hopkins RO,Mir-Kasimov M,Sevin CM,Turnbull AE,Jackson JC,Needham DM,Caraker E,Cherukuri SPS,Kadiri NP,Kalva T,Koneru M,Kota P,Lee EM,Mahmoud MA,Malik A,Nikooie R,Roberts D,Singu S,Vaziri P,Brown K,Daw A,Merrill M,Smith R,Hirshberg E,Butler J,Hoenig B,Karamourtopoulos M,Hays M,Abel R,High C,Beck E,Armbruster B,Applegate D,Fergus M,Kumar N,Roth M,Mogan S,Abel R,De Souza Licht A,Londono I,Larson J,Capers K,Karamourtopoulos M,Hoenig B,Toksoz-Exley A,Crane (2022). Association between unmet medication needs after hospital discharge and readmission or death among acute respiratory failure survivors: the addressing post-intensive care syndrome (APICS-01) multicenter prospective cohort study. Critical care (London, England), 26(1), (Read full article)
  89. Wheeler DC,Jongs N,Stefansson BV,Chertow GM,Greene T,Hou FF,Langkilde AM,McMurray JJV,Rossing P,Nowicki M,Wittmann I,Correa-Rotter R,Sjöström CD,Toto RD,Heerspink HJ (2022). Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. American journal of kidney diseases, 37(9), 1647-1656. (Read full article)
  90. Li JW,Arnott C,Heerspink HJL,Mbiostat QL,Cannon CP,Wheeler DC,Charytan DM,Barraclough J,Figtree GA,Agarwal R,Bakris G,de Zeeuw D,Greene T,Levin A,Pollock C,Zhang H,Zinman B,Mahaffey KW,Perkovic V,Neal B,Jardine M (2022). Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. American journal of kidney diseases, 11(16), (Read full article)
  91. Li Y,He Y,Falzon I,Fairbourn B,Tingey S,Imrey PB,Radeva MK,Beck GJ,Gassman JJ,Roy-Chaudhury P,Berceli SA,Cheung AK,Shiu YT,Feldman H,Dember L,Farber A,Kaufman J,Stern L,LeSage P,Kivork C,Soares D,Malikova M,Allon M,Young C,Taylor M,Woodard L,Mangadi K,Munda R,Lee T,Alloway R,El-Khatib M,Canaan T,Pflum A,Thieken L,Campos-Naciff B,Huber T,Berceli S,Jansen M,McCaslin G,Trahan Y,Vazquez M,Vongpatanasin W,Davidson I,Hwang C,Lightfoot T,Livingston C,Valencia A,Dolmatch B,Fenves A,Hawkins N,Cheung A,Kraiss L,Kinikini D,Treiman G,Ihnat D,Sarfati M,Lavasani I,Maloney M,Schlotfeldt L,Himmelfarb J,Buchanan C,Clark C,Crawford C,Hamlett J,Kundzins J,Manahan L,Wise J,Beck G,Gassman J,Greene T,Imrey P,Li L,Alster J,Li M,MacKrell J,Radeva M,Weiss B,Wiggins K,Alpers C,Hudkins K,Wietecha T,Robbin M,Umphrey H,Alexander L,Abts C,Belt L,Vita J,Hamburg N,Duess M,Levit A,Higgins H,Ke S,Mandaci O,Snell C,Gravley J,Behnken S,Mortensen R,Chertow G,Besarab A,Brayman (2022). Dynamic Remodeling of Human Arteriovenous Fistula Wall Obtained From Magnetic Resonance Imaging During the First 6 Months After Creation. American journal of kidney diseases, 7(8), 1905-1909. (Read full article)
  92. Cohen JB,Marcum ZA,Zhang C,Derington CG,Greene TH,Ghazi L,Herrick JS,King JB,Cheung AK,Bryan N,Supiano MA,Sonnen JA,Weintraub WS,Scharfstein D,Williamson J,Pajewski NM,Bress A (2022). Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data from the Systolic Blood Pressure Intervention Trial (SPRINT). American journal of kidney diseases, 5(7), E2220680. (Read full article)
  93. Marrouche NF,Wazni O,McGann C,Greene T,Dean JM,Dagher L,Kholmovski E,Mansour M,Marchlinski F,Wilber D,Hindricks G,Mahnkopf C,Wells D,Jais P,Sanders P,Brachmann J,Bax JJ,Morrison-De Boer L,Deneke T,Calkins H,Sohns C,Akoum (2022). Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial. American journal of kidney diseases, 327(23), 2296-2305. (Read full article)
  94. Sisco-Taylor BL,Magel JS,McFadden M,Greene T,Shen J,Fritz J (2022). Changes in Pain Catastrophizing and Fear-Avoidance Beliefs as Mediators of Early Physical Therapy on Disability and Pain in Acute Low-Back Pain: A Secondary Analysis of a Clinical Trial. American journal of kidney diseases, 23(6), 1127-1137. (Read full article)
  95. Vonesh EF,Greene (2022). Biased estimation with shared parameter models in the presence of competing dropout mechanisms. American journal of kidney diseases, 78(1), 399-406. (Read full article)
  96. Neuen BL,Tighiouart H,Heerspink HJL,Vonesh EF,Chaudhari J,Miao S,Chan TM,Fervenza FC,Floege J,Goicoechea M,Herrington WG,Imai E,Jafar TH,Lewis JB,Li PKT,Locatelli F,Maes BD,Perrone RD,Praga M,Perna A,Schena FP,Wanner C,Wetzels JFM,Woodward M,Xie D,Greene T,Inker L (2022). Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. American journal of kidney diseases, 33(2), 291-303. (Read full article)
  97. Marcum ZA,Cohen JB,Zhang C,Derington CG,Greene TH,Ghazi L,Herrick JS,King JB,Cheung AK,Bryan N,Supiano MA,Sonnen JA,Weintraub WS,Williamson J,Pajewski NM,Bress A (2022). Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors with Cognitive Impairment. American journal of kidney diseases, 5(1), E2145319. (Read full article)
  98. Raimann JG,Chan CT,Daugirdas JT,Depner T,Greene T,Kaysen GA,Kliger AS,Kotanko P,Larive B,Beck G,Lindsay RMG,Rocco MV,Chertow GM,Levin N (2021). The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials. American journal of kidney diseases, 46(6), 768-776. (Read full article)
  99. Beddhu S,Boucher RE,Sun J,Balu N,Chonchol M,Navaneethan S,Chertow GM,Townsend R,Haley W,Cheung AK,Conroy MB,Raj DS,Xu D,George T,Yunis R,Wei G,Canton G,Bates J,Chen J,Papademetriou V,Punzi H,Wiggers A,Wright JT,Greene T,Yuan (2021). Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. American journal of kidney diseases, 22(1), (Read full article)
  100. Toth DJA,Beams AB,Keegan LT,Zhang Y,Greene T,Orleans B,Seegert N,Looney A,Alder SC,Samore M (2021). High variability in transmission of SARS-CoV-2 within households and implications for control. American journal of kidney diseases, 16(11 November), (Read full article)
  101. Samore MH,Looney A,Orleans B,Greene T,Seegert N,Delgado JC,Presson A,Zhang C,Ying J,Zhang Y,Shen J,Slev P,Gaulin M,Yang MJ,Pavia AT,Alder S (2021). Probability-based estimates of severe acute respiratory syndrome coronavirus 2 seroprevalence and detection fraction, utah, usa. American journal of kidney diseases, 27(11), 2786-2794. (Read full article)
  102. Heerspink HJL,Jongs N,Chertow GM,Langkilde AM,McMurray JJV,Correa-Rotter R,Rossing P,Sjöström CD,Stefansson BV,Toto RD,Wheeler DC,Greene (2021). Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. American journal of kidney diseases, 9(11), 743-754. (Read full article)
  103. Jongs N,Greene T,Chertow GM,McMurray JJV,Langkilde AM,Correa-Rotter R,Rossing P,Sjöström CD,Stefansson BV,Toto RD,Wheeler DC,Heerspink HJ (2021). Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. American journal of kidney diseases, 9(11), 755-766. (Read full article)
  104. Wheeler DC,Toto RD,Stefánsson BV,Jongs N,Chertow GM,Greene T,Hou FF,McMurray JJV,Pecoits-Filho R,Correa-Rotter R,Rossing P,Sjöström CD,Umanath K,Langkilde AM,Heerspink HJ (2021). A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. American journal of kidney diseases, 100(1), 215-224. (Read full article)
  105. Vonesh EF,Greene (2021). Correction: Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease (Statistics in Medicine, (2019), 38, 22, (4218-4239), 10.1002/sim.8282). American journal of kidney diseases, 40(14), 3400-3401. (Read full article)
  106. Nelson RE,Montgomery AE,Suo Y,Cook J,Pettey W,Gundlapalli A,Greene T,Evans W,Gelberg L,Kertesz SG,Tsai J,Byrne T (2021). Temporary financial assistance decreased health care costs for veterans experiencing housing instability. American journal of kidney diseases, 40(5), 820-828. (Read full article)
  107. Inker LA,Couture SJ,Tighiouart H,Abraham AG,Beck GJ,Feldman HI,Greene T,Gudnason V,Karger AB,Eckfeldt JH,Kasiske BL,Mauer M,Navis G,Poggio ED,Rossing P,Shlipak MG,Levey AS,Andresdottir MB,Gudmundsdottir H,Indridason OS,Palsson R,Kimmel P,Weir M,Kalil R,Pesavento T,Porter A,Taliercio J,Hsu Cy,Chen J,Sinkeler S,Wyatt C,Krishnasami Z,Hellinger J,Margolick J,Kingsley L,Witt M,Wolinsky S,Shafi T,Post W,Doria A,Parving H (2021). A New Panel-Estimated GFR, Including ß2-Microglobulin and ß-Trace Protein and Not Including Race, Developed in a Diverse Population. American journal of kidney diseases, 77(5), 673-683.e1. (Read full article)
  108. Bress AP,Greene T,Derington CG,Shen J,Xu Y,Zhang Y,Ying J,Bellows BK,Cushman WC,Whelton PK,Pajewski NM,Reboussin D,Beddu S,Hess R,Herrick JS,Zhang Z,Kolm P,Yeh RW,Basu S,Weintraub WS,Moran A (2021). Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. American journal of kidney diseases, 77(16), 1977-1990. (Read full article)
  109. Heerspink HJL,Sjöström CD,Jongs N,Chertow GM,Kosiborod M,Hou FF,McMurray JJV,Rossing P,Correa-Rotter R,Kurlyandskaya R,Stefansson BV,Toto RD,Langkilde AM,Wheeler DC,Heerspink HJL,Wheeler DC,Chertow GM,Correa-Rotter R,Greene T,McMurray J,Rossing P,Toto R,Stefansson BV,Maria Langkilde A,Maffei LE,Raffaele P,Solis SE,Arias CA,Aizenberg D,Luquez C,Zaidman C,Cluigt N,Mayer M,Alvarisqueta A,Wassermann A,Maldonado R,Bittar J,Maurich M,Gaite LE,Garcia N,Sivak L,Ramallo PO,Santos JC,Garcia Duran R,Oddino JA,Maranon A,Maia LN,D Avila D,Barros EJG,Vidotti MH,Panarotto D,Noronha IDL,Turatti LAA,Deboni L,Canziani ME,Riella MC,Bacci MR,Paschoalin RP,Franco RJ,Goldani JC,St-Amour E,Steele AW,Goldenberg R,Pandeya S,Bajaj H,Cherney D,Kaiser SM,Conway JR,Chow SS,Bailey G,Lafrance J,Winterstein J,Cournoyer S,Gaudet D,Madore F,Houlden RL,Dowell A,Langlois M,Muirhead N,Khandwala H,Levin A,Xue Y,Zuo L,Hao C,Ni Z,Xing C,Chen N,Dong Y,Zhou R,Xiao X,Zou Y,Wang C,Liu B,Chen Q,Lin M,Luo Q,Zhang D,Wang J,Chen M,Wang (2021). Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial. American journal of kidney diseases, 42(13), 1216-1227. (Read full article)
  110. Cho ME,Sweeney C,Fino N,Greene T,Ramkumar N,Huang Y,Ricardo AC,Shafi T,Deo R,Anderson A,Mills KT,Cheung A (2021). Longitudinal changes in prorenin and renin in the chronic renal insufficiency cohort. American journal of kidney diseases, 52(2), 141-151. (Read full article)
  111. Marrouche NF,Greene T,Dean JM,Kholmovski EG,Boer LMd,Mansour M,Calkins H,Marchlinski F,Wilber D,Hindricks G,Mahnkopf C,Jais P,Sanders P,Brachmann J,Bax J,Dagher L,Wazni O,Akoum (2021). Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design. American journal of kidney diseases, 32(4), 916-924. (Read full article)
  112. Oshima M,Jardine MJ,Agarwal R,Bakris G,Cannon CP,Charytan DM,de Zeeuw D,Edwards R,Greene T,Levin A,Lim SK,Mahaffey KW,Neal B,Pollock C,Rosenthal N,Wheeler DC,Zhang H,Zinman B,Perkovic V,Heerspink HJ (2021). Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. American journal of kidney diseases, 99(4), 999-1009. (Read full article)
  113. McMurray JJV,Wheeler DC,Stefánsson BV,Jongs N,Postmus D,Correa-Rotter R,Chertow GM,Greene T,Held C,Hou FF,Mann JFE,Rossing P,Sjöström CD,Toto RD,Langkilde AM,Heerspink HJ (2021). Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 143(5), 438-448. (Read full article)
  114. Brintz BJ,Haaland B,Howard J,Chao DL,Proctor JL,Khan AI,Ahmed SM,Keegan LT,Greene T,Keita AM,Kotloff KL,Platts-Mills JA,Nelson EJ,Levine AC,Pavia AT,Leung D (2021). A modular approach to integrating multiple data sources into real-time clinical prediction for pediatric diarrhea. eLife, 10, 1-18. (Read full article)
  115. Lyden K,Boucher R,Wei G,Zhou N,Christensen J,Chertow GM,Beddhu S,Greene (2021). Targeting sedentary behavior in ckd a pilot and feasibility randomized controlled trial. Clinical journal of the American Society of Nephrology, 16(5), 717-726. (Read full article)
  116. Cho ME,Hansen JL,Sauer BC,Cheung AK,Agarwal A,Greene (2021). Heart failure hospitalization risk associated with iron status in veterans with ckd. Clinical journal of the American Society of Nephrology, 16(4), 522-531. (Read full article)
  117. Jardine M,Zhou Z,Lambers Heerspink HJ,Hockham C,Li Q,Agarwal R,Bakris GL,Cannon CP,Charytan DM,Greene T,Levin A,Li JW,Neuen BL,Neal B,Oh R,Oshima M,Pollock C,Wheeler DC,de Zeeuw D,Zhang H,Zinman B,Mahaffey KW,Perkovic (2021). Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis. Clinical journal of the American Society of Nephrology, 16(3), 384-395. (Read full article)
  118. Bakris G,Oshima M,Mahaffey KW,Agarwal R,Cannon CP,Capuano G,Charytan DM,de Zeeuw D,Edwards R,Greene T,Heerspink HJL,Levin A,Neal B,Oh R,Pollock C,Rosenthal N,Wheeler DC,Zhang H,Zinman B,Jardine MJ,Perkovic (2020). Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial. Clinical journal of the American Society of Nephrology, 15(12), 1705-1714. (Read full article)
  119. Inker LA,Grams ME,Levey AS,Coresh J,Cirillo M,Collins JF,Gansevoort RT,Gutierrez OM,Hamano T,Heine GH,Ishikawa S,Jee SH,Kronenberg F,Landray MJ,Miura K,Nadkarni GN,Peralta CA,Rothenbacher D,Schaeffner E,Sedaghat S,Shlipak MG,Zhang L,van Zuilen AD,Hallan SI,Kovesdy CP,Woodward M,Levin A,Astor B,Appel L,Greene T,Chen T,Chalmers J,Arima H,Perkovic V,Yatsuya H,Tamakoshi K,Li Y,Hirakawa Y,Matsushita K,Sang Y,Polkinghorne K,Chadban S,Atkins R,Djurdjev O,Liu L,Zhao M,Wang F,Wang J,Ebert N,Martus P,Tang M,Emrich I,Seiler S,Zawada A,Nally J,Navaneethan S,Schold J,Sarnak M,Katz R,Hiramoto J,Iso H,Yamagishi K,Umesawa M,Muraki I,Fukagawa M,Maruyama S,Hasegawa T,Fujii N,Wheeler D,Emberson J,Townend J,Brenner H,Schöttker B,Saum KU,Fox C,Hwang SJ,Köttgen A,Schneider MP,Eckardt KU,Green J,Kirchner HL,Chang AR,Ho K,Ito S,Miyazaki M,Nakayama M,Yamada G,Irie F,Sairenchi T,Yano Y,Kotani K,Nakamura T,Kimm H,Mok Y,Chodick G,Shalev V,Wetzels JFM,Blankestijn PJ,van den Brand J,Kollerits (2019). Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American journal of kidney diseases, 73(2), 206-217. (Read full article)
  120. Gou E,Weng C,Greene T,Anderson KE,Phillips J (2018). Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria. The journal of applied laboratory medicine, 3(2), 213-221. (Read full article)
  121. Baigent C,Herrington WG,Coresh J,Landray MJ,Levin A,Perkovic V,Pfeffer MA,Rossing P,Walsh M,Wanner C,Wheeler DC,Winkelmayer WC,McMurray JJV,Abu-Alfa A,Archdeacon P,Block GA,Caskey FJ,Cheung AK,Cooper B,Craig JC,Dember LM,Eknoyan G,Gansevoort RT,Gill JS,Gillespie B,Greene T,Harris DC,Haynes R,Hemmelgarn BR,Herzog CA,Hiemstra TF,Inker LA,Jardine MJ,Jha V,Jiang L,Johansen KL,Kewalramani R,Lambers Heerspink HJ,Lefkowitz M,Lok CE,Loud F,Ma¿iulaitis R,Maddux DW,Maddux FW,Madero M,Mariz S,Mauer M,Nally JV,Nangaku M,Okpechi IG,Parfrey PS,Pecoits-Filho R,Pereira BJG,Rocco MV,Rossignol P,Schaefer F,Tentori F,Thompson A,Tonelli M,Tong A,Toto RD,Tuttle KR,Vetter T,Moon Wang AY,Zannad (2017). Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease&mdash;Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international, 92(2), 297-305. (Read full article)
  122. Unruh ML,Larive B,Eggers PW,Garg AX,Gassman JJ,Finkelstein FO,Kimmel PL,Chertow GM,Achinger S,Anderson S,Appel L,Apruzzes R,Atwal J,Augustine B,Ayus J,Bardsley J,Bay W,Beach S,Beck G,Bharti B,Briggs J,Bullas R,Burkart J,Burrowes J,Cabezon E,Callegari J,Carter M,Champagne J,Chan C,Chan W,Chang J,Cheung A,Copland M,Coplon N,Coppley A,Daugirdas J,Dellagrottaglie S,Depner T,Derse A,Dominguez A,Doss S,Eknoyan G,Escalada R,Fensterer A,Fofie Y,Franzwa B,Frome R,Fu Z,Gayda P,Geller N,Geronemus R,Goodman W,Gorodetskaya I,Gotch F,Greene T,Greenwood R,Grimm R,Gutierrez M,Hall Y,Handelman G,Henderson L,Hernandez A,Higgins H,Hilkin A,Hostetter T,Hoy C,Humphreys M,Hunsicker L,James S,Kariisa M,Kaufman A,Kaufman T,Kaysen G,Ke S,Keene R,Kliger A,Kotanko P,Kramer C,Kuhlmann M,Kwan S,Kwok S,Lacson E,Leavell E,Lemus D,Levin A,Levin N,Li M,Lilli K,Lindsay R,Lockridge R,Luan J,Mackrell J,Manaster R,Mandaci O,Mathew R,Mauck V,Mazzorato A,McCulloch C,McGrath-Chong M,McLeroy (2016). The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials. Nephrology, dialysis, transplantation, 31(6), 984-991. (Read full article)
  123. Farber A,Imrey PB,Huber TS,Kaufman JM,Kraiss LW,Larive B,Li L,Feldman HI,Dember L,Stern L,Lesage P,Kivork C,Soares D,Malikova M,Allon M,Young C,Taylor M,Woodard L,Mangadi K,Roy-Chaudhury P,Munda R,Lee T,Alloway R,El-Khatib M,Canaan T,Pflum A,Thieken L,Campos-Naciff B,Berceli S,Jansen M,McCaslin G,Trahan Y,Vazquez M,Vongpatanasin W,Davidson I,Hwang C,Lightfoot T,Livingston C,Valencia A,Dolmatch B,Fenves A,Hawkins N,Cheung A,Kinikini D,Treiman G,Ihnat D,Sarfati M,Lavasani I,Maloney M,Schlotfeldt L,Himmelfarb J,Buchanan C,Clark C,Crawford C,Hamlett J,Kundzins J,Manahan L,Wise J,Beck G,Gassman J,Greene T,Alster J,Li M,Mackrell J,Radeva M,Weiss B,Wiggins K,Alpers C,Hudkins K,Wietecha T,Robbin M,Umphrey H,Alexander L,Abts C,Belt L,Vita J,Hamburg N,Duess M,Levit A,Higgins H,Ke S,Mandaci O,Snell C,Gravley J,Behnken S,Mortensen R,Chertow G,Besarab A,Brayman K,Diener-West M,Harrison D,Inker L,Louis T,McClellan W,Rubin J,Kusek J,Star (2016). Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study. Journal of vascular surgery, 63(1), 163-170.e6. (Read full article)
  124. Wen CP,Matsushita K,Coresh J,Iseki K,Islam M,Katz R,McClellan W,Peralta CA,Wang HY,De Zeeuw D,Astor BC,Gansevoort RT,Levey AS,Levin A,Wright JT,Appel L,Greene T,Chalmers J,MacMahon S,Woodward M,Arima H,Yatsuya H,Yamashita K,Toyoshima H,Tamakoshi K,Sang Y,Atkins RC,Polkinghorne KR,Chadban S,Shankar A,Klein R,Klein BEK,Lee KE,Wang F,Zhang L,Zuo L,Liu L,Djurdjev O,Tonelli M,Sacks F,Curhan G,Shlipak M,Fried L,Iso H,Kitamura A,Ohira T,Yamagishi K,Jafar TH,Hatcher J,Poulter N,Chaturvedi N,Landray MJ,Emberson J,Townend J,Wheeler DC,Rothenbacher D,Brenner H,Müller H,Schöttker B,Fox CS,Hwang SJ,Meigs JB,Perkins RM,Fluck N,Clark L,Prescott GJ,Marks A,Black C,Cirillo M,Hallan S,Aasard K,Øien CM,Radtke M,Irie F,Sairenchi T,Smith DH,Weiss J,Johnson ES,Thorp ML,Collins AJ,Vassalotti JA,Li S,Chen SC,Lee BJ,Wetzels JF,Blankestijn PJ,Van Zuilen AD,Sarnak M,Inker L,Menon V,Fried LF,Kramer H,De Boer I,Kronenberg F,Kollerits B,Ritz E,Roderick P,Nitsch D,Fletcher A,Bulpitt (2014). Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney international, 86(4), 819-827. (Read full article)
  125. Suri RS,Larive B,Hall Y,Kimmel PL,Kliger AS,Levin N,Tamura MK,Chertow GM,Levin NW,Beck GJ,Depner TA,Eggers P,Gassman JJ,Gorodetskaya I,Greene T,James S,Lindsay RM,Mehta RL,Miller B,Ornt DB,Rajagopalan S,Rastogi A,Rocco MV,Schiller B,Sergeyeva O,Schulman G,Ting GO,Unruh ML,Star RA,Lockridge RS,Chan CT,Copland M,Hoy CD,Pierratos A,Pipkin MF,Stokes JB,Briggs J,Hostetter T,Narva A,Star RA,Augustine B,Mohr P,Fu Z,Daugirdas J,Hunsicker L,Li M,Mackrell J,Wiggins K,Sherer S,Weiss B,Sanz J,Dellagrottaglie S,Kariisa M,Tran T,West J,Keene R,Schlarb J,McGrath-Chong M,Frome R,Higgins H,Ke S,Mandaci O,Owens C,Snell C,Eknoyan G,Appel L,Cheung A,Derse A,Kramer C,Geller N,Grimm R,Henderson L,Prichard S,Roecker E,Riley J,Schuessler R,Peterson C,Fensterer A,Steigerwald D,Somers D,Hilkin A,Lilli K,Wallace W,Franzwa B,Waterman E,Levin A,Sioson L,Cabezon E,Kwan S,Roger D,Champagne J,Bullas R,Garg A,Mazzorato A,Spanner E,Burkart J,Moossavi S,Mauck V,Kaufman T,Chan (2014). Effects of frequent hemodialysis on perceived caregiver burden in the frequent hemodialysis network trials. Clinical journal of the American Society of Nephrology, 9(5), 936-942. (Read full article)
  126. Budtz-Jørgensen E,Bellinger D,Lanphear B,Grandjean P,Hornung R,Khoury J,Yolton K,Baghurst P,Canfield RL,Dietrich KN,Bornschein R,Greene T,Rothenberg SJ,Needleman HL,Schnaas L,Wasserman G,Graziano J,Roberts (2013). An international pooled analysis for obtaining a benchmark dose for environmental lead exposure in children. Risk analysis, 33(3), 450-461. (Read full article)
  127. Chertow G,Levin N,Beck G,Depner T,Eggers P,Gassman J,Gorodetskaya I,Greene T,James S,Larive B,Lindsay R,Mehta R,Miller B,Ornt D,Rajagopalan S,Rastogi A,Rocco M,Schiller B,Sergeyeva O,Schulman G,Ting G,Unruh M,Star R,Kliger (2010). In-center hemodialysis six times per week versus three times per week. The New England journal of medicine, 363(24), 2287-2300. (Read full article)
  128. Rogers RK,Stehlik J,Stoddard GJ,Greene T,Collins SP,Peacock WF,Maisel AD,Clopton P,Michaels A (2010). Erratum: Corrigendum to 'Adjusting for clinical covariates improves the ability of b-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: A sub-study of HEARD-IT' (Eur J Heart Fail (2009) 11 (1043-1049)). European journal of heart failure, 12(5), 524-525. (Read full article)
  129. Levey AS,Coresh J,Greene T,Stevens LA,Zhang Y,Hendriksen (2008). Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)). Annals of internal medicine, 149(7), 519. (Read full article)
  130. Dixon BS,Beck GJ,Dember LM,Depner TA,Gassman JJ,Greene T,Himmelfarb J,Hunsicker LG,Kaufman JS,Lawson JH,Meyers CM,Middleton JP,Radeva M,Schwab SJ,Whiting JF,Feldman H (2006). Erratum: Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial (Clinical Trials 2 (400-412)). Clinical trials (London, England), 3(2), 160. (Read full article)
  131. Sarnak M,Wang S,Beck G,Kusek J,Selhub J,Greene T,Levey (2002). Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. American journal of kidney diseases, 40(5), 932-939. (Read full article)
  132. Ray P,Acheson D,Chitrakar R,Cnaan A,Gibbs K,Hirschman GH,Christen E,Trachtman H,Ingelfinger J,Briggs J,Kusek J,Cattran D,Cohen MB,Freeman K,Greene T,Moshe S,Schulman S,Springate J,Kaskel F,Whyte D,Weiss R,McKay C,Reisman L,Perelstein E,Chandra M,Salcedo J,Weiss L,Varade W,Ford D,Chan J,Restaino I,Nagaraj S,Norwood V,Foreman J,Moritz M,Mahan J,Moxey-Mims M,Warshaw B,Yiu V,Brem A,Bartosh S,Andreoli S,Milner L,Goebel J,Muchant D,Hanevold (2002). Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. Journal of the American Society of Nephrology, 13(3), 699-707. (Read full article)
  133. Beddhu S,Kaysen G,Yan G,Sarnak M,Agodoa L,Ornt D,Cheung A,Greene T,Beck G,Gassman (2002). Association of serum albumin and atherosclerosis in chronic hemodialysis patients. American journal of kidney diseases, 40(4), 721-727. (Read full article)
  134. Levey AS,Adler S,Caggiula AW,England BK,Greene T,Hunsicker LG,Kusek JW,Rogers NL,Teschan P (1996). Effects of dietary protein restriction on the progression of moderate renal disease in the modification of diet in renal disease study: Modification of Diet in Renal Disease Study Group. Journal of the American Society of Nephrology, 7(12), 2616-2626. (Read full article)
  135. Levey AS,Beck GJ,Bosch JP,Caggiula AW,Greene T,Hunsicker LG,Klahr (1996). Short-Term Effects of Protein Intake, Blood Pressure, and Antihypertensive Therapy on Glomerular Filtration Rate in the Modification of Diet in Renal Disease Study. Journal of the American Society of Nephrology, 7(10), 2097-2109. (Read full article)
  136. Nelson S,Greene T,Ernhart (1996). Toxocara canis infection in preschool age children: Risk factors and the cognitive development of preschool children. Neurotoxicology and teratology, 18(2), 167-174. (Read full article)
  137. Coggins CH,Dwyer JT,Greene T,Petot G,Snetselaar LG,Lente F (1994). Serum Lipid Changes Associated With Modified Protein Diets: Results From the Feasibility Phase of the Modification of Diet in Renal Disease Study. American journal of kidney diseases, 23(4), 514-523. (Read full article)
  138. Fritz JM,Del Fiol G,Gibson B,Wetter DW,Solis V,Bennett E,Thackeray A,Goode A,Lundberg K,Romero A,Ford I,Stevens L,Siaperas T,Morales J,Yack M,Greene (2022). BeatPain Utah: study protocol for a pragmatic randomised trial examining telehealth strategies to provide non-pharmacologic pain care for persons with chronic low back pain receiving care in federally qualified health centers. BMJ open, 12(11), (Read full article)
  139. Jongs N,Chertow GM,Greene T,McMurray JJV,Langkilde AM,Correa-Rotter R,Kashihara N,Rossing P,Sjöström CD,Stefánsson BV,Toto RD,Wheeler DC,Heerspink HJL,Hou F (2022). Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. Journal of the American Society of Nephrology, 33(11), 2094-2107. (Read full article)
  140. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress A (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension (Dallas, Tex., 80(7), 1484-1493. (Read full article)
  141. Chang TI, Wei G, Boucher R, Kramer H, Chertow GM, Cheung AK, Greene T, Whelton PK, Beddhu (2020). Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. Kidney360, 1(5), 368-375. (Read full article)
  142. Schlechter CR, Del Fiol G, Lam CY, Fernandez ME, Greene T, Yack M, Schulthies S, Nelson M, Bohner C, Pruhs A, Siaperas T, Kawamoto K, Gibson B, Nahum-Shani I, Walker TJ, Wetter D (2021). Application of community - engaged dissemination and implementation science to improve health equity. Preventive medicine reports, 24, 101620. (Read full article)
  143. Fritz JM, Rhon DI, Garland EL, Hanley AW, Greenlee T, Fino N, Martin B, Highland KB, Greene (2022). The Effectiveness of a Mindfulness-Based Intervention Integrated with Physical Therapy (MIND-PT) for Post-Surgical Rehabilitation after Lumbar Surgery: A Protocol for a Randomized Controlled Trial as Part of the Back Pain Consortium (BACPAC) Research Program. Pain medicine (Malden, Mass.), 24(Suppl 1), S115-S125. (Read full article)
  144. Jones BE, Ying J, Nevers MR, Alba PR, Patterson OV, Peterson KS, Rutter E, Christensen MA, Stern S, Jones MM, Gundlapalli A, Dean NC, Samore MC, Greene (2022). Trends in Illness Severity, Hospitalization, and Mortality for Community-Onset Pneumonia at 118 US Veterans Affairs Medical Centers. Journal of general internal medicine, 37(15), 3839-3847. (Read full article)
  145. Yao Y, Li L, Astor B, Yang W, Greene (2023). Predicting the risk of a clinical event using longitudinal data: the generalized landmark analysis. BMC medical research methodology, 23(1), 5. (Read full article)
  146. Baron KG, Appelhans BM, Burgess HJ, Quinn L, Greene T, Allen C (2023). Circadian Timing, Information processing and Metabolism (TIME) study: protocol of a longitudinal study of sleep duration, circadian alignment and cardiometabolic health among overweight adults. BMC endocrine disorders, 23(1), 26. (Read full article)
  147. Vanneman ME, Rosen AK, Wagner TH, Shwartz M, Gordon SH, Greenberg G, Zheng T, Cook J, Beilstein-Wedel E, Greene T, Kelley A (2023). Differences Between VHA-Delivered and VHA-Purchased Behavioral Health Care in Service and Patient Characteristics. Psychiatric services (Washington, D.C.), 74(2), 148-157. (Read full article)
  148. Bose S, Groat D, Dinglas VD, Akhlaghi N, Banner-Goodspeed V, Beesley SJ, Greene T, Hopkins RO, Mir-Kasimov M, Sevin CM, Turnbull AE, Jackson JC, Needham DM, Brown SM, Addressing Post-Intensive Care Syndrome (APICS-01) Study Tea (2023). Association Between Unmet Nonmedication Needs After Hospital Discharge and Readmission or Death Among Acute Respiratory Failure Survivors: A Multicenter Prospective Cohort Study. Critical care medicine, 51(2), 212-221. (Read full article)
  149. Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (2023). Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clinical journal of the American Society of Nephrology, 18(2), 183-192. (Read full article)
  150. Fritz JM, Greene T, Brennan GP, Minick K, Lane E, Wegener ST, Skolasky R (2023). Characterizing modifications to a comparative effectiveness research study: the OPTIMIZE trial-using the Framework for Reporting Adaptations and Modifications to Evidence-based Interventions (FRAME). Trials, 24(1), 137. (Read full article)
  151. Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King J (2023). Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension (Dallas, Tex., 80(3), 590-597. (Read full article)
  152. Spivak AM, Barney BJ, Greene T, Holubkov R, Olsen CS, Bridges J, Srivastava R, Webb B, Sebahar F, Huffman A, Pacchia CF, Dean JM, Hess (2023). A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. Microbiology spectrum, 11(2), e0467422. (Read full article)
  153. Jones BE, Ying J, Nevers M, Rutter ED, Chapman AB, Brenner R, Samore MH, Greene (2023). Hospital admission decisions for older Veterans with community-onset pneumonia: An analysis of 118 U.S. Veterans Affairs Medical Centers. Academic emergency medicine, 30(4), 398-409. (Read full article)
  154. Eneanya ND, Adingwupu OM, Kostelanetz S, Norris KC, Greene T, Lewis JB, Beddhu S, Boucher R, Miao S, Chaudhari J, Levey AS, Inker L (2023). Social Determinants of Health and Their Impact on the Black Race Coefficient in Serum Creatinine-Based Estimation of GFR: Secondary Analysis of MDRD and CRIC Studies. Clinical journal of the American Society of Nephrology, 18(4), 446-454. (Read full article)
  155. Ghazi L, Shen J, Ying J, Derington CG, Cohen JB, Marcum ZA, Herrick JS, King JB, Cheung AK, Williamson JD, Pajewski NM, Bryan N, Supiano M, Sonnen J, Weintraub WS, Greene TH, Bress A (2023). Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. JAMA network open, 6(5), e2314443. (Read full article)
  156. Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine M (2023). The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes, obesity & metabolism, (Read full article)
  157. Heerspink HJL, Inker LA, Tighiouart H, Collier WH, Haaland B, Luo J, Appel GB, Chan TM, Estacio RO, Fervenza F, Floege J, Imai E, Jafar TH, Lewis JB, Kam-Tao Li P, Locatelli F, Maes BD, Perna A, Perrone RD, Praga M, Schena FP, Wanner C, Xie D, Greene T, CKD-EPI C (2023). Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD. Journal of the American Society of Nephrology, 34(6), 955-968. (Read full article)
  158. van der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, Levin A, Mahaffey KW, Pollock C, Greene T, Wheeler DC, Jardine MJ, Heerspink HJ (2023). Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. Clinical journal of the American Society of Nephrology, 18(6), 748-758. (Read full article)
  159. Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL, CKD-EPI Clinical Trials Consortiu (2023). A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature medicine, (Read full article)
  160. Derington CG, Bress AP, Berchie RO, Herrick JS, Shen J, Ying J, Greene T, Tajeu GS, Sakhuja S, Ruiz-Negrón N, Zhang Y, Howard G, Levitan EB, Muntner P, Safford MM, Whelton PK, Weintraub WS, Moran AE, Bellows BK, SPRINT Research Grou (2023). Estimated population health benefits of intensive systolic blood pressure treatment among SPRINT-eligible US adults. American journal of hypertension, 36(9), 498-508. (Read full article)
  161. Heerspink HJL, Jongs N, Neuen BL, Schloemer P, Vaduganathan M, Inker LA, Fletcher RA, Wheeler DC, Bakris G, Greene T, Chertow GM, Perkovic (2023). Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney international, 104(1), 181-188. (Read full article)
  162. Inker LA,Chaudhari J,Greene T,Gucciardo A,Heerspink HJ (2024). The Collaborative Nephrology Community: Perspectives and Experience on Data Sharing. Journal of the American Society of Nephrology, 35(1), 98-101. (Read full article)
  163. Abat S,Abd Rahman R,Abdul Cader R,Abdul Hafidz MI,Abdul Wahab MZ,Abdullah NK,Abdul-Samad T,Abe M,Abraham N,Acheampong S,Achiri P,Acosta JA,Adeleke A,Adell V,Adewuyi-Dalton R,Adnan N,Africano A,Agharazii M,Aguilar F,Aguilera A,Ahmad M,Ahmad MK,Ahmad NA,Ahmad NH,Ahmad NI,Ahmad Miswan N,Ahmad Rosdi H,Ahmed I,Ahmed S,Aiello J,Aitken A,AitSadi R,Aker S,Akimoto S,Akinfolarin A,Akram S,Alberici F,Albert C,Aldrich L,Alegata M,Alexander L,Alfaress S,Alhadj Ali M,Ali A,Alicic R,Aliu A,Almaraz R,Almasarwah R,Almeida J,Aloisi A,Al-Rabadi L,Alscher D,Alvarez P,Al-Zeer B,Amat M,Ambrose C,Ammar H,An Y,Andriaccio L,Ansu K,Apostolidi A,Arai N,Araki H,Araki S,Arbi A,Arechiga O,Armstrong S,Arnold T,Aronoff S,Arriaga W,Arroyo J,Arteaga D,Asahara S,Asai A,Asai N,Asano S,Asawa M,Asmee MF,Aucella F,Augustin M,Avery A,Awad A,Awang IY,Awazawa M,Axler A,Ayub W,Azhari Z,Baccaro R,Badin C,Bagwell B,Bahlmann-Kroll E,Bahtar AZ,Baigent C,Bains D,Bajaj H,Baker R,Baldini E,Banas B,Banerjee D,Banno (2024). Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. The lancet. Diabetes & endocrinology, 12(1), 51-60. (Read full article)
  164. Staplin N,Haynes R,Judge PK,Wanner C,Green JB,Emberson J,Preiss D,Mayne KJ,Ng SYA,Sammons E,Zhu D,Hill M,Stevens W,Wallendszus K,Brenner S,Cheung AK,Liu ZH,Li J,Hooi LS,Liu WJ,Kadowaki T,Nangaku M,Levin A,Cherney D,Maggioni AP,Pontremoli R,Deo R,Goto S,Rossello X,Tuttle KR,Steubl D,Petrini M,Seidi S,Landray MJ,Baigent C,Herrington WG,Abat S,Abd Rahman R,Abdul Cader R,Abdul Hafidz MI,Abdul Wahab MZ,Abdullah NK,Abdul-Samad T,Abe M,Abraham N,Acheampong S,Achiri P,Acosta JA,Adeleke A,Adell V,Adewuyi-Dalton R,Adnan N,Africano A,Agharazii M,Aguilar F,Aguilera A,Ahmad M,Ahmad MK,Ahmad NA,Ahmad NH,Ahmad NI,Ahmad Miswan N,Ahmad Rosdi H,Ahmed I,Ahmed S,Aiello J,Aitken A,AitSadi R,Aker S,Akimoto S,Akinfolarin A,Akram S,Alberici F,Albert C,Aldrich L,Alegata M,Alexander L,Alfaress S,Alhadj Ali M,Ali A,Alicic R,Aliu A,Almaraz R,Almasarwah R,Almeida J,Aloisi A,Al-Rabadi L,Alscher D,Alvarez P,Al-Zeer B,Amat M,Ambrose C,Ammar H,An Y,Andriaccio L,Ansu K,Apostolidi A,Arai N,Araki H,Araki (2024). Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. The lancet. Diabetes & endocrinology, 12(1), 39-50. (Read full article)
  165. Baron KG,Duffecy J,Simonsen S,Bress A,Conroy MB,Greene T,Allen C,Vallejo (2023). Sleep Technology Intervention to Target Cardiometabolic Health (STITCH): a randomized controlled study of a behavioral sleep extension intervention compared to an education control to improve sleep duration, blood pressure, and cardiometabolic health among adults with elevated blood pressure/hypertension. Trials, 24(1), (Read full article)
  166. Collier W,Haaland B,Inker L,Greene (2023). Handling missing within-study correlations in the evaluation of surrogate endpoints. Statistics in medicine, 42(26), 4738-4762. (Read full article)
  167. Najjar M,McCarron J,Scheffer Cliff ER,Berger K,Steensma DP,Al Hadidi S,Chakraborty R,Goodman A,Anto E,Greene T,Sborov D,Mohyuddin G (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA network open, 6(11), E2342195. (Read full article)
  168. Yi TW,Smyth B,Di Tanna GL,Arnott C,Cardoza K,Kang A,Pollock C,Agarwal R,Bakris G,Charytan DM,de Zeeuw D,Heerspink HJL,Neal B,Wheeler DC,Cannon CP,Zhang H,Zinman B,Perkovic V,Levin A,Mahaffey KW,Jardine M,Brenner BM,Greene T,Meininger G,Li N,Kolesnyk I,Aizenberg D,Pecoits-Filho R,Cherney D,Obrador G,Chertow G,Chang T,Hawley C,Ji L,Wada T,Jha V,Lim SK,Lim-Abrahan MA,Santos F,Chae DW,Hwang SJ,Vazelov E,Rychlík I,Hadjadj S,Krane V,Rosivall L,De Nicola L,Dreval A,Nowicki M,Schiller A,Distiller L,Górriz JL,Kolesnyk M,David,Wheeler C,Guerrero RAA,Albisu JP,Alvarisqueta A,Bartolacci I,Berli MA,Bordonava A,Calella P,Cantero MC,Cartasegna LR,Cercos E,Coloma GC,Colombo H,Commendatore V,Cuadrado J,Cuneo CA,Cusumano AM,Douthat WG,Dran RD,Farias E,Fernandez MF,Finkelstein H,Fragale G,Fretes JO,Garcia NH,Gastaldi A,Gelersztein E,Glenny JA,Gonzalez JP,Colaso PdCG,Goycoa C,Greloni GC,Guinsburg A,Hermida S,Juncos LI,Klyver MI,Kraft F,Krynski F,Lanchiotti PV,Leon de la Fuente RA,Marchetta N,Mele P,Nicolai S,Novoa PA,Orio SI,Otreras (2023). Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. American journal of kidney diseases, 82(1), 84-96.e1. (Read full article)
  169. Nelson RE,Montgomery AE,Suo Y,Cook J,Pettey W,Evans W,Greene T,Gelberg L,Kertesz S,Tsai J,Byrne (2022). The Impact of Temporary Housing Assistance Expenditures on Subcategories of Health Care Cost for U.S. Veterans Facing Housing Instability. Journal of health care for the poor and underserved, 33(4), 1821-1843. (Read full article)
  170. Jacobs JA, Derington CG, Zheutlin AR, King JB, Cohen JB, Bucheit J, Kronish IM, Addo DK, Morisky DE, Greene TH, Bress A (2024). Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Journal of the American Heart Association, 13(3), e031574. (Read full article)
  171. Kennedy E, Ozmen M, Bouldin ED, Panahi S, Mobasher H, Troyanskaya M, Martindale SL, Merritt VC, O'Neil M, Sponheim SR, Remigio-Baker RA, Presson A, Swan AA, Werner JK, Greene TH, Wilde EA, Tate DF, Walker WC, Pugh M (2024). Phenotyping Depression After Mild Traumatic Brain Injury: Evaluating the Impact of Multiple Injury, Gender, and Injury Context. Journal of neurotrauma, 41(7-8), 924-933. (Read full article)
  172. Metz TD, Allshouse AA, McMillin GA, Greene T, Chung JH, Grobman WA, Haas DM, Mercer BM, Parry S, Reddy UM, Saade GR, Simhan HN, Silver R (2023). Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function. JAMA, 330(22), 2191-2199. (Read full article)
  173. Fino NF, Adingwupu OM, Coresh J, Greene T, Haaland B, Shlipak MG, Costa E Silva VT, Kalil R, Mindikoglu AL, Furth SL, Seegmiller JC, Levey AS, Inker L (2023). Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation. Kidney international, 105(3), 582-592. (Read full article)
  174. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen J (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. Journal of the American Heart Association, 12(17), e030311. (Read full article)
  175. Rathinagopal T, Bhanot S, Yegrov S, Min J, Hu N, Fang J, Greene TH, Varma Shrivastav S, Singh H, Shrivastav (2022). N-myristoyltransferase 2-based Blood Test for the Detection of Colorectal Adenomatous Polyps and Cancer. Annals of surgery open, 3(1), e117. (Read full article)
  176. Collier W, Haaland B, Inker LA, Heerspink HJL, Greene (2024). Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials. BMC medical research methodology, 24(1), 39. (Read full article)
  177. Yan G, Nee R, Scialla JJ, Greene T, Yu W, Heng F, Cheung AK, Norris K (2024). Role of Age and Competing Risk of Death in the Racial Disparity of Kidney Failure Incidence after Onset of CKD. Journal of the American Society of Nephrology, 35(3), 299-310. (Read full article)
  178. McKee KE, Knighton AJ, Veale K, Martinez J, McCann C, Anderson JW, Wolfe D, Blackburn R, McKasson M, Bardsley T, Ofori-Atta B, Greene TH, Hoesch R, Püttgen HA, Srivastava (2024). Impact of Local Tailoring on Acute Stroke Care in 21 Disparate Emergency Departments: A Prospective Stepped Wedge Type III Hybrid Effectiveness-Implementation Study. Circulation. Cardiovascular quality and outcomes, 17(5), e010477. (Read full article)
  179. Conroy MB, Cedillo M, Jordanova K, Zepeda J, Kiraly B, Flynn M, Wu C, Kukhareva PV, Butler JM, Hess R, Greene T, Kawamoto (2024). Implementing weight maintenance with existing staff and electronic health record tools in a primary care setting: Baseline results from the MAINTAIN PRIME trial. Contemporary clinical trials, 141, 107520. (Read full article)
  180. Ku E, Inker LA, Tighiouart H, McCulloch CE, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Hou FF, Toto RD, Li PK, Sarnak M (2024). Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials. Annals of internal medicine, 177(7), 953-963. (Read full article)
  181. Pajewski NM, Beddhu S, Bress AP, Chang TI, Chertow GM, Cheung AK, Cushman WC, Freedman BI, Greene T, Johnson KC, Jaeger BC, Tamura MK, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Williamson JD, Whelton PK, Wright JT Jr, Drawz PE, Ix J (2024). The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation. Journal of the American Society of Nephrology, 35(12), 1737-1745. (Read full article)
  182. Cooper M, Cherney DZI, Greene TH, Heerspink HJL, Jardine M, Lewis JB, Wong MG, Baquero E, Heise M, Jochems J, Lanchoney D, Liss C, Reiser D, Scotney P, Velkoska E, Dwyer J (2024). Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial. Journal of the American Society of Nephrology, 35(11), 1546-1557. (Read full article)
  183. Akoum N, Mekhael M, Bisbal F, Wazni O, McGann C, Lee H, Bardsley T, Greene T, Dean JM, Dagher L, Kholmovski E, Mansour M, Marchlinski F, Wilber D, Hindricks G, Mahnkopf C, Wells D, Jaïs P, Sanders P, Brachmann J, Bax JJ, Morrison-de Boer L, Deneke T, Calkins H, Sohns C, Marrouche N, DECAAF II investigator (2024). Lesion delivery and scar formation in catheter ablation for atrial fibrillation: The DECAAF II trial. Heart rhythm, (Read full article)
  184. King JB, Sakhuja S, Derington CG, Kolm P, Herrick JS, Berchie RO, Shen J, Greene T, Tajeu GS, Howard G, Levitan EB, Muntner P, Safford MM, Ying J, Weintraub WS, Moran AE, Bress AP, Bellows B (2024). Annual Cost of Implementing Intensive Systolic Blood Pressure Goals in the United States. Journal of the American Heart Association, 13(18), e034515. (Read full article)
  185. Sideris K, Zhang M, Wolhfahrt P, Siu AF, Shen J, Carter S, Kyriakopoulos CP, Taleb I, Wever-Pinzon O, Shah K, Selzman CH, Rodriguez-Correa C, Kapelios C, Brinker L, Alharethi R, Hess R, Drakos SG, Steinberg BA, Fang JC, Kfoury AG, Melenovsky V, Greene T, Spertus JA, Stehlik (2024). Integration of Patient Reported Quality of Life Data into Risk Assessment in Heart Failure. Journal of cardiac failure, 31(5), 761-770. (Read full article)
  186. Coon ER, Greene T, Fritz J, Desai AD, Ray KN, Hersh AL, Bardsley T, Bonafide CP, Brady PW, Wallace SS, Schroeder AR, FAAN'C Trial Grou (2024). A multicenter randomized trial to compare automatic versus as-needed follow-up for children hospitalized with common infections: The FAAN-C trial protocol. Journal of hospital medicine, 19(10), 977-987. (Read full article)
  187. Ku E, Tighiouart H, McCulloch CE, Inker LA, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Hou FF, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Toto RD, Sarnak M (2024). Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes. Journal of the American Society of Nephrology, 35(10), 1402-1411. (Read full article)
  188. Heerspink HJL, Eddington D, Chaudhari J, Estacio R, Imai E, Goicoechea M, Hannedouche T, Haynes R, Jafar TH, Johnson DW, van Kruijsdijk RCM, Lewis JB, Li PKT, Neuen BL, Perrone RD, Ruggenenti P, Wanner C, Woodward M, Xie D, Greene T, Inker L (2024). A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection. Kidney international, 106(4), 688-698. (Read full article)
  189. Schlechter CR, Kuzmenko TV, Orleans B, Wirth J, Kaphingst KA, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Dinkins CP, Greene T, Zhang Y, Chipman JJ, Friedrichs M, Lam CY, Pierce JH, Borsato EP, Cornia RC, Stevens L, Martinez A, Bradshaw RL, Hess R, Fiol GD, Wetter D (2024). Reach and Engagement With Population Health Management Interventions to Address COVID-19 Among Safety-Net Health Care Systems. American journal of public health, 114(11), 1207-1211. (Read full article)
  190. Kim Y,Bu S,Tao C,Bae KT,Steinman T,Wei J,Czarnecki P,Pedrosa I,Braun W,Nurko S,Remer E,Chapman A,Martin D,Rahbari-Oskoui F,Mittal P,Torres V,Hogan MC,El-Zoghby Z,Harris P,Glockner J,King B,Perrone R,Halin N,Miskulin D,Schrier R,Brosnahan G,Gitomer B,Kelleher C,Masoumi A,Patel N,Winklhofer F,Grantham J,Yu A,Wang C,Wetzel L,Moore CG,Bost JE,Bae KT,Abebe KZ,Miller JP,Thompson PA,Briggs J,Flessner M,Meyers CM,Star R,Shayman J,Henrich W,Greene T,Leonard M,McCullough P,Moe S,Rocco M,Wendler (2024). Deep Learning'Based Automated Imaging Classification of ADPKD. Kidney international reports, 9(6), 1802-1809. (Read full article)
  191. Del Fiol G,Orleans B,Kuzmenko TV,Chipman J,Greene T,Martinez A,Wirth J,Meads R,Kaphingst KK,Gibson B,Kawamoto K,King AJ,Siaperas T,Hughes S,Pruhs A,Pariera Dinkins C,Lam CY,Pierce JH,Benson R,Borsato EP,Cornia R,Stevens L,Bradshaw RL,Schlechter CR,Wetter D (2024). SCALE-UP II: protocol for a pragmatic randomised trial examining population health management interventions to increase the uptake of at-home COVID-19 testing in community health centres. BMJ open, 14(3), (Read full article)
  192. Snyder AM,Stone CJ,Ufkes N,Greene T,Playdon MC,Murtaugh MA,Vanneman ME,Secrest A (2024). Lifestyle, medication use, and age considerations with acne vulgaris: A prospective study. JEADV clinical practice, (Read full article)
  193. El Hajjar AH,Dagher L,Younes H,Mekhael M,Noujaim C,Chouman N,Greene T,Pandey AC,Huang C,Marrouche (2024). History of stroke as a predictor of high left atrial fibrosis in patients with persistent atrial fibrillation'insight from the DECAAF II randomized trial. Journal of interventional cardiac electrophysiology, (Read full article)
  194. He Y,Shiu YT,Imrey PB,Radeva MK,Beck GJ,Gassman JJ,Northrup HM,Roy-Chaudhury P,Berceli SA,Cheung AK,Feldman H,Dember L,Farber A,Kaufman J,Stern L,LeSage P,Kivork C,Soares D,Malikova M,Allon M,Young C,Taylor M,Woodard L,Mangadi K,Munda R,Lee T,Alloway R,El-Khatib M,Canaan T,Pflum A,Thieken L,Campos-Naciff B,Huber T,Berceli S,Jansen M,McCaslin G,Trahan Y,Vazquez M,Vongpatanasin W,Davidson I,Hwang C,Lightfoot T,Livingston C,Valencia A,Dolmatch B,Fenves A,Hawkins N,Cheung A,Kraiss L,Kinikini D,Treiman G,Ihnat D,Sarfati M,Lavasani I,Maloney M,Schlotfeldt L,Himmelfarb J,Buchanan C,Clark C,Crawford C,Hamlett J,Kundzins J,Manahan L,Wise J,Beck G,Gassman J,Greene T,Imrey PB,Li L,Alster J,Li M,MacKrell J,Radeva MK,Weiss B,Wiggins K,Alpers C,Hudkins K,Wietecha T,Robbin M,Umphrey H,Alexander L,Abts C,Belt L,Vita J,Hamburg N,Duess M,Levit A,Higgins H,Ke S,Mandaci O,Snell C,Gravley J,Behnken S,Mortensen R,Chertow G,Besarab A,Brayman K,Diener-West M,Harrison D,Inker (2023). Association of Shear Stress with Subsequent Lumen Remodeling in Hemodialysis Arteriovenous Fistulas. Clinical journal of the American Society of Nephrology, 18(1), 72-83. (Read full article)
  195. Anker SD,Butler J,Filippatos G,Böhm M,Brunner-La Rocca HP,Choi DJ,Chopra V,Chuquiure'Valenzuela E,Giannetti N,Gomez'Mesa JE,Janssens S,Januzzi JL,Gonzalez-Juanatey JR,Merkely B,Nicholls SJ,Perrone SV,Piña IL,Ponikowski P,Senni M,Sim D,Spinar J,Squire I,Taddei S,Tsutsui H,Verma S,Vinereanu D,Zhang J,Carson P,Lam CSP,Marx N,Zeller C,Sattar N,Jamal W,Schnaidt S,Schnee JM,Brueckmann M,Zannad F,Packer M,Palmer M,Parhofer KG,Pedersen TR,Konstam MA,Lees KR,Carson P,Doehner W,Miller A,Haas M,Pehrson S,Komajda M,Anand I,Teerlink J,Rabinstein A,Steiner T,Kamel H,Tsivgoulis G,Lewis J,Freston J,Kaplowitz N,Mann J,Petrie J,Perrone SV,Nicholls SJ,Janssens S,Bocchi E,Giannetti N,Verma S,Jian Z,Gomez Mesa JE,Spinar J,Boehm M,Chopra V,Senni M,Taddei S,Tsutsui H,Choi DJ,Chuquiure E,La Rocca HPB,Vinereanu D,Sim D,Gonzalez Juanatey JR,Squire I,Januzzi JL,Pina I,Bernstein R,Cheung A,Green J,Kaul S,Ping CLS,Lip G,Marx N,McCullough P,Mehta C,Rosenstock J,Scirica B,Shah S,Verma S,Wanner C,Aizenberg D,Cartasegna L,Colombo (2021). Empagliflozin in heart failure with a preserved ejection fraction. The New England journal of medicine, 385(16), 1451-1461. (Read full article)

Review

  1. Siew ED,Liu KD,Bonn J,Chinchilli V,Dember LM,Girard TD,Greene T,Hernandez AF,Alp Ikizler T,James MT,Kampschroer K,Kopp JB,Levy M,Palevsky PM,Pannu N,Parikh CR,Rocco MV,Silver SA,Thiessen-Philbrook H,Wald R,Xie Y,Kimmel PL,Star R (2020). Improving care for patients after hospitalization with AKI. Journal of the American Society of Nephrology, 31(10), 2237-2241. (Read full article)
  2. Nkoy FL, Fassl BA, Wilkins VL, Johnson JM, Unsicker EH, Koopmeiners KJ, Jensen A, Frazier M, Gaddis J, Malmgren L, Williams S, Poll JB, Greene TH, Sheng X, Uchida DA, Maloney CG, Stone B (2019). (Read full article)
  3. Metz TD,Allshouse AA,McMillin GA,Greene T,Chung JH,Grobman WA,Haas DM,Mercer BM,Parry S,Reddy UM,Saade GR,Simhan HN,Silver R (2024). Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function. Obstetrical & gynecological survey, 79(6), 307-309. (Read full article)

Editorial

  1. Greene T, Li (2017). From Static to Dynamic Risk Prediction: Time Is Everything. American journal of kidney diseases, 69(4), 492-494. (Read full article)
  2. Cheung AK, Greene (2009). Effect of membrane permeability on survival of hemodialysis patients. Journal of the American Society of Nephrology, 20(3), 462-4. (Read full article)
  3. Li L, Yang W, Astor BC, Greene (2019). Competing Risk Modeling: Time to Put it in Our Standard Analytical Toolbox. Journal of the American Society of Nephrology, 30(12), 2284-2286. (Read full article)

Letter

  1. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Greene T, Wei G, Boucher R, Whelton PK, SPRINT Research Group (2018). Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". Circulation, 137(24), 2668-2669. (Read full article)
  2. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey K (2020). Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation, 141(5), 407-410. (Read full article)
  3. Presson AP, Greene TH, Ou Z, Zhang C, Tyser AR, Kazmers N (2021). Reply to "The Problem of Collinearity in Mental Health and Patient Reported Outcome Research". The Journal of hand surgery, 46(2), e3-e6. (Read full article)
  4. Brown KA, Daneman N, Stevens V, Greene TH, Arora (2016). Reply to Wolkewitz: When to Use Cumulative Risk-Based Versus Rate-Based Approaches in the Analysis of Hospital-Acquired Infection Risk Factors? That Depends on the Question. Infection control and hospital epidemiology, 37(9), 1124-5. (Read full article)
  5. Joseph JV, Greene (2008). Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillonneau J Urol 2007; 178: 120-124. The Journal of urology, 179(2), 789-90. (Read full article)
  6. Levey AS, Coresh J, Tighiouart H, Greene T, Inker L (2019). Strengths and limitations of estimated and measured GFR. Nature reviews. Nephrology, 15(12), 784. (Read full article)
  7. Yan G,Nee R,Scialla JJ,Greene T,Yu W,Cheung AK,Norris K (2022). Estimation of Black-White Disparities in CKD Outcomes: Comparison Using the 2021 Versus the 2009 CKD-EPI Creatinine Equations. American journal of kidney diseases, 80(3), 423-426. (Read full article)
  8. Inker LA,Heerspink HJL,Vonesh EF,Greene (2022). Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure". Circulation. Heart failure, 15(3), E008983. (Read full article)
  9. Sarraju A,Li JW,Cannon CP,Chang TI,Agarwal R,Bakris G,Charytan DM,de Zeeuw D,Greene T,Heerspink HJL,Levin A,Neal B,Pollock C,Wheeler DC,Yavin Y,Zhang H,Zinman B,Perkovic V,Jardine M,Mahaffey K (2021). Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American heart journal, 233, 141-148. (Read full article)

Other

  1. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress A (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PloS one, 16(4), e0248080. (Read full article)